Impaired immune cell cytotoxicity in severe COVID-19 is IL-6 dependent

Alessio Mazzoni, …, Francesco Annunziato, Lorenzo Cosmi


**Graphical abstract**
Impaired immune cell cytotoxicity in severe COVID-19 is IL-6 dependent

Alessio Mazzoni,1 Lorenzo Salvati,1 Laura Maggi,1 Manuela Capone,1 Anna Vanni,1 Michele Spinicci,1,2 Jessica Mencarini,1,2 Roberto Caporale,1 Benedetta Peruzzi,3 Alberto Antonelli,1 Michele Trotta,2 Lorenzo Zammarchi,1,2 Luca Ciani,1 Leonardo Gori,1 Chiara Lazzeri,4 Andrea Matucci,5 Alessandra Vultaggio,1 Oliviero Rossi,1 Fabio Almerigogna,1,5 Paola Parronchi,1,6 Paolo Fontanari,7 Federico Lavorini,1,8 Adriano Peris,4 Gian Maria Rossolini,1,8 Alessandro Bartoloni,1,2 Sergio Romagnani,1 Francesco Liotta,1,9 Francesco Annunziato,1,3 and Lorenzo Cosmi1,6

1Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy. 2Flow Cytometry Diagnostic Center and Immunotherapy (CDCI), 3Intensive Care Unit and Regional Extracorporeal Membrane Oxygenation (ECMO) Referral Centre, 4Immunonallergology Unit, 5Immunology and Cell Therapy Unit, 6Cardiac Anesthesia and Intensive Care Unit, 7Pneumology and Intensive Care Unit, and 8Clinical Microbiology and Virology Unit, Careggi University Hospital, Florence, Italy.

BACKGROUND. Coronavirus disease 19 (COVID-19) is an emerging infectious disease caused by SARS-CoV-2. Antiviral immune response is crucial to achieve pathogen clearance; however, in some patients an excessive and aberrant host immune response can lead to an acute respiratory distress syndrome. The comprehension of the mechanisms that regulate pathogen elimination, immunity, and pathology is essential to better characterize disease progression and widen the spectrum of therapeutic options.

METHODS. We performed a flow cytometric characterization of immune cell subsets from 30 patients with COVID-19 and correlated these data with clinical outcomes.

RESULTS. Patients with COVID-19 showed decreased numbers of circulating T, B, and NK cells and exhibited a skewing of CD8+ T cells toward a terminally differentiated/senescent phenotype. In agreement, CD4+ T and CD8+ T, but also NK cells, displayed reduced antiviral cytokine production capability. Moreover, a reduced cytotoxic potential was identified in patients with COVID-19, particularly in those who required intensive care. The latter group of patients also showed increased serum IL-6 levels that inversely correlated to the frequency of granzyme A–expressing NK cells. Off-label treatment with tocilizumab restored the cytotoxic potential of NK cells.

CONCLUSION. The association between IL-6 serum levels and the impairment of cytotoxic activity suggests the possibility that targeting this cytokine may restore antiviral mechanisms.

FUNDING. This study was supported by funds from the Department of Experimental and Clinical Medicine of University of Florence (the ex-60% fund and the “Excellence Departments 2018–2022 Project”) derived from Ministero dell’Istruzione, dell’Università e della Ricerca (Italy).

Introduction

SARS-CoV-2 is the etiological agent of coronavirus disease 19 (COVID-19) and belongs to the same group of RNA viruses that caused SARS and Middle East respiratory syndrome (MERS) in the past (1–3). At the time of this publication, the WHO considered COVID-19 to be a new pandemic disease (4). As of June 30, 2020, there have been 10,185,374 confirmed COVID-19 cases globally; in Italy, 240,436 confirmed cases have been reported, with a total of 34,744 deaths (5). Coronavirus are enveloped, nonsegmented, single-stranded, positive-sense RNA viruses named after the observation on electron microscopy of their crown-like surface projections that correspond to large surface spike proteins. Coronavirus are classified in the Nidovirales order (6). These viruses are host specific and can infect humans and a variety of animals as well. The previously unknown coronavirus, named SARS-CoV-2, was discovered in December 2019 in Wuhan, in the province of Hubei, China, and was sequenced and isolated by January 2020 (7–9). SARS-CoV, MERS-CoV, and SARS-CoV-2 are all in the genus Betacoronavirus (6). SARS-CoV-2 infection clinically presents with fever, nonproductive cough, and respiratory distress that tends to be more common in adults than in children (10). Coronavirus entry into host cells is mediated by the transmembrane spike (S) glycoprotein that forms homotrimers protruding from the viral surface (11). SARS-CoV and several SARS-related coronaviruses
Results

Clinical evaluation of patients with COVID-19. We evaluated 30 patients affected by COVID-19 who were admitted to Careggi University Hospital. SARS-CoV-2 infection was confirmed by positive reverse transcription real-time PCR on nasopharyngeal swab in accordance with WHO interim guidance (24). All specimens were restested and deemed positive for SARS-CoV-2 by the Italian NIH. The clinical characteristics of the 30 patients are shown in Supplemental Table 1 (supplemental material available online with this article; https://doi.org/10.1172/JCI138554DS1). The median age of the patients was 70 years (range 36–85 years), the mean age was 65.9 years, and 60% of the patients were male. The mean age was 67.9 years for men and 63 years for women. On the day of the immunological analysis, which was performed on average 9.2 days after the onset of the disease and 3.5 days after the hospital admission, the most common symptoms were fever (53%) and cough (40%), whereas diarrhea was an uncommon manifestation (3%). All patients presented with chest imaging abnormalities (Supplemental Table 1); the most frequent radiological findings were pulmonary consolidations (40%) and multiple, bilateral, patchy opacities (30%), compatible with interstitial pneumonia.

Supplemental Table 2 reports laboratory results on the day of immunological analysis. Lymphocytopenia (median 830 cells/μL) was present in 93% of the patients, with a median neutrophil/lymphocyte ratio of 7.3 and eosinopenia (median 20 cells/μL) in 52% of patients. Almost all patients had elevation of acute-phase proteins: C-reactive protein (CRP, median 60.5 mg/L), fibrinogen (median 510 mg/dL), and ferritin (median 795 mg/mL). D-dimer interact directly with angiotensin-converting enzyme 2 (ACE2) via the S protein to enter target cells (12, 13). It has been recently shown that ACE2 can also mediate SARS-CoV-2 S-dependent entry into cells, thus representing a functional receptor for this newly emerged coronavirus (14). ACE2 is expressed in the respiratory tract, by mucosal epithelial cells, lung alveolar type 2 pneumocytes, and arterial and venous endothelial cells but also in other tissues, including the gastrointestinal tract, accounting for the mild enteritis that sometimes is present in patients with COVID-19 (15, 16).

Both innate and adaptive immune responses are critical for the control of viral infections. NK cells exert the primary control during acute viral infection, but cytotoxic CD8+ T lymphocytes (CTLs) are critical for long-term surveillance (17–20). The antiviral effects of NK and CD8+ T cells can be mediated by direct cytotoxicity or through the release of IFN-γ. IFN-γ is able to directly interfere with viral replication, as well as to indirectly affect viral clearance through the activation of Th1-mediated responses and through MHC class I pathway enhancement (21). Antiviral cytotoxic responses are mediated principally by perforin and granzymes. Recovery from viral infections requires the generation of effective antiviral responses that can eliminate, or at least control, the infecting pathogen. Severe viral infections may induce per se immunopathology; however, dysregulated antiviral immune responses can contribute to tissue damage. Thus, it is important to understand the mechanisms regulating pathogen elimination, immunity, and pathology to prevent immune-mediated damage (22, 23).

In trying to treat common infections, it is important to understand the mechanisms that regulate pathogen elimination, immunity, and pathology so that immune-mediated damage is prevented. The aim of the present study was to perform a deep immunophenotyping of PBMCs from patients affected by COVID-19 and to correlate these data with clinical parameters and outcomes.
Each population. Data obtained from 8 healthy controls and 21 COVID-19 patients. *P < 0.05; **P < 0.01; ***P < 0.001; calculated with Student’s t test.

PaO2/FiO2 ratio 171 vs. 314, mean SaO2/FiO2 ratio 170 vs. 372, nary involvement than patients not admitted to the ICU (mean PaO2/FiO2 ratio was 261 (median 268) (Supplemental Table 3). Oxygen therapy was being administered in 77% of the patients; the mean PaO2/FiO2 ratio was 261 (median 268) (Supplemental Table 3). Acute respiratory distress syndrome (ARDS) during the course of COVID-19 occurred in 14 cases (53%). Among the 30 hospitalized patients considered in this study, 12 (40%) were admitted to the intensive care unit (ICU). ICU patients had more severe pulmonary involvement than patients not admitted to the ICU (mean PaO2/FiO2 ratio 171 vs. 314, mean SaO2/FiO2 ratio 170 vs. 372, mean alveolar-arterial O2 gradient 326 vs. 72 mmHg, respectively) (P < 0.001). In addition, these patients presented higher neutrophil and lower lymphocyte counts (P < 0.05), higher neutrophil/lymphocyte ratio (P < 0.01), higher lactate dehydrogenase (P < 0.001), as well as higher CRP (P < 0.05) and IL-6 (P < 0.01) compared with the non-ICU patients.

Patients with COVID-19 are characterized by lymphopenia. In order to provide direct evaluation of leukocyte homeostasis, we studied the immunological characteristics of peripheral blood leukocytes derived from patients infected with SARS-CoV-2. As shown in Figure 1A, patients with COVID-19 were characterized by a significant increase of neutrophils and a significant decrease of absolute numbers of lymphocytes, eosinophils, and basophils in the peripheral blood as compared with age- and sex-matched healthy controls. Total leukocytes’ and monocytes’ absolute numbers were comparable between patients with COVID-19 and healthy controls (Figure 1A). In order to better understand which lymphocyte population was affected, we performed a flow cytometric analysis of circulating leukocytes. As shown in Figure 1B, absolute numbers of T cells (CD3+), B cells (CD3 CD19+), and NK cells (CD3 CD56+) were significantly reduced in patients with COVID-19 when compared with healthy controls. In addition, among CD3+ cells, we found a significant reduction of CD4+, CD8+, and CD56+ (NKT) cells (Figure 1C). More importantly, we found that the CD4+/CD8+ T cell ratio in patients with COVID-19 was significantly higher than in healthy controls (Figure 1D). The frequencies of TCR αβ- and γδ-positive T lymphocytes showed no significant differences in patients with COVID-19 compared with healthy controls, as well as the frequencies of Treg and T follicular helper cells (data not shown).

CD3+CD8+ lymphocytes from patients with COVID-19 have a senescent phenotype. Because all lymphocyte populations were significantly reduced in patients with COVID-19, we evaluated, in the context of B and T lymphocytes, whether the frequencies of the different subpopulations at different stages of maturation varied.

As shown in Supplemental Figure 1, A–E, although the frequency of naive (IgD+CD27-), memory-nonswitched (IgD+CD27+), memory-switched (IgD+CD27+), and B lymphocytes and plasmablasts (CD27+CD38+) was not significantly affected, the frequency of transitional (IgM+CD38+) B lymphocytes was significantly reduced (P < 0.001) in patients with COVID-19 when compared with reference ranges (25).

In the context of CD4+ T lymphocytes, we found a significant increase in the frequency of T central memory (Tcm, CD45RA-CCR7) cells, whereas naive (CD45RA+CCR7), T effector memory (Tem, CD45RA CCR7), T effector memory CD45RA- (TEMRA, CD45RA+CCR7), and HLA-DR+ cells from patients with COVID-19 did not show different values when compared with healthy controls (Figure 2A and Supplemental Figure 2). Because the total count of CD4+ T cells was significantly lower in COVID-19 patients than in healthy controls, this finding means that among CD4+ T cells, the naive, Tem, and TEMRA subsets were mostly impaired in these patients, whereas Tcm were relatively conserved.

More importantly, flow cytometric analysis of CD8+ T lymphocytes revealed a statistically significant reduction of...
Cytokines described as being highly protective against viral infections, i.e., IFN-γ, TNF-α, and IL-2. As shown in Figure 3A, patients with COVID-19 showed a significantly increased frequency of IL-2–producing CD4+ T cells, whereas CD8+ T lymphocytes of the same patients showed a significantly reduced frequency of IL-2 when compared with healthy controls.

Patients with COVID-19 showed a significantly reduced frequency of IFN-γ–producing CD4+ and CD8+ T cells when compared with healthy controls (Figure 3B). No differences were found in NK cells (Figure 3B) in terms of IFN-γ production.

Furthermore, patients with COVID-19 showed a significantly reduced frequency of TNF-α–producing NK cells when compared with healthy controls (Figure 3C). It should be noted that the CD4+ and CD8+ T lymphocytes also showed a reduced ability to produce TNF-α even if these data did not reach statistical significance (Figure 3C). Because it has been shown that CD4+ and CD8+ T cells able to produce more than 1 cytokine (polymorphic T cells) are most protective against viral infections.
(26), we simultaneously evaluated IL-2, IFN-γ, and TNF-α expression on a cohort of patients with COVID-19, as well as healthy controls (Supplemental Figure 4A). As shown in Supplemental Figure 4, B and C, although no differences were detected in CD4+ T cells between COVID-19 patients and healthy controls, significantly reduced frequencies of IL-2+IFN-γ+TNF-α+ and IL-2+IFN-γ+TNF-α-CD8+ T cells within COVID-19 patients were detected.

Because the antiviral effects of lymphocytes can also be exerted by direct cytotoxicity mediated primarily by perforin and granzymes, we evaluated the cytoplasmic expression of these 2 molecules in CD4+ T lymphocytes, CD8+ T lymphocytes, and NK cells to define their cytotoxic potential (Supplemental Figure 5). As shown in Figure 3, D and E, NK cells from COVID-19 patients showed significantly reduced percentages of both perforin and granzyme A as compared with healthy donors. Although CD3+CD4+ T cells from COVID-19 patients showed significantly reduced frequencies of granzyme A, no differences were appreciable regarding the frequency of perforin+ cells in this cell subset and of perforin and granzyme A in the CD3+CD8+ T cell population (Figure 3, D and E).

COVID-19 patients admitted to the ICU show significantly reduced NK cell numbers and cytotoxic potential. A significant fraction of patients with COVID-19 develop ARDS and need hospitalization in the ICU, requiring invasive mechanical ventilation (27). We therefore investigated whether there was a significant variation of the previously identified immune parameters between patients who were admitted to the ICU (ICU patients) and those not admitted to the ICU (non-ICU patients) during the course of hospitalization.

As shown in Figure 4A, ICU patients were characterized by a significant increase of neutrophils’ absolute numbers and a significant decrease of lymphocytes’ absolute numbers in the peripheral blood as compared with non-ICU patients. Total leukocytes as well as absolute numbers of monocytes, eosinophils, and basophils were comparable between the 2 groups of patients (Figure 4A). As shown in Figure 4B, flow cytometric analysis of circulating leukocytes revealed that absolute numbers of T cells (CD3+ and NK cells (CD3CD56+), but not B cells (CD19+), were significantly reduced in ICU patients compared with non-ICU patients. In addition, among CD3+ cells, we found a significant reduction of CD4+ cells, but not CD8+ and CD56+ (NKT) cells, in ICU patients compared with non-ICU patients (Figure 4C). In the context of CD4+ T lymphocytes, we found no significant differences in the frequency of naive (CD45RACCR7+), Tem (CD45RACCR7+), TEMRA (CD45RACCR7+), or HLA-DR+ cells between the 2 groups of patients (Figure 4D).

In contrast, flow cytometric analysis of CD8+ T lymphocytes revealed statistically significant reduction of Tem (CD45RACCR7+) cells and increase of TEMRA (CD45RACCR7+) in ICU patients compared with non-ICU patients (Figure 4E). As shown in Figure 4E, naive (CD45RACCR7+), Tem (CD45RACCR7+), senescent (CD57+), and HLA-DR+CD8+ T cells did not differ between the 2 groups of patients (Figure 4E).

As shown in Figure 5, A–C, no differences were identified between the 2 groups of patients regarding the frequencies of CD3+CD4+, CD3+CD8+, and NK cells producing IFN-γ, TNF-α, and IL-2. Regarding T cell polyfunctionality, our analysis performed on a cohort of ICU patients and non-ICU patients showed no statistically significant differences between the 2 groups (Supplemental Figure 6).

Finally, the frequencies of both perforin and granzyme A were reduced in NK cells from ICU patients, with statistical significance only for granzyme A (Figure 5, D and E). All together, these data support the concept that in ICU patients the depletion of CD3+CD4+ T cells becomes even more pronounced, as well as the accumulation of terminally differentiated CD3+CD8+ T cells and NK cells with reduced cytolytic potential, leading to altered immunological protection.

High IL-6 serum levels in ICU patients inversely correlate with NK cytotoxic potential, which can be restored by tocilizumab treatment. Because SARS-CoV-2 infection is reportedly associated with increased IL-6 serum levels (28), we evaluated this proinflammatory cytokine in the sera of ICU and non-ICU patients. As shown in Figure 6A, IL-6 serum levels were significantly higher in ICU patients compared with non-ICU patients. More importantly, among those cellular parameters that we found significantly altered in ICU versus non-ICU patients, we observed a significant inverse correlation only between the serum levels of IL-6 and the frequency of NK cells expressing granzyme A (Figure 6B).

Because higher serum IL-6 levels correlated with lower granzyme A expression on NK cells, we investigated whether blocking the IL-6 axis in COVID-19 patients with tocilizumab could restore granzyme A expression. For this reason, we recruited 5 ICU patients as candidates for tocilizumab treatment, characterized by high IL-6 serum levels and low frequency of NK cells expressing granzyme A. Tocilizumab treatment led to a reduction of CRP levels, suggesting that efficacious neutralization of IL-6 activity was achieved (Figure 6C). As shown in Figure 6D, an increased lymphocyte count was observed after tocilizumab treatment. From a functional point of view, no significant increase was observed in the frequencies of CD8+ T cells expressing granzyme A or perforin (Figure 6, E and F). However, treatment with tocilizumab significantly increased the expression of granzyme A and perforin on NK cells (Figure 6, G and H) and induced a mild amelioration of the PaO2/FiO2 ratio in 4 out of 5 patients (Figure 6I).

Discussion
Cytotoxic lymphocytes such as CD8+ T lymphocytes and NK cells are necessary for the control of viral infections (17–20), and the functional exhaustion of these cells is correlated with disease progression (29, 30). In contrast, exaggerated or uncontrolled immune responses can be responsible for the organ damage that sometimes accompanies the infection (16, 21). The aim of our work was to perform a phenotypic and functional characterization of the immune response in patients infected with SARS-CoV-2 hospitalized at the Careggi University Hospital, Florence, Italy.

We enrolled 30 patients whose main clinical features are reported in Supplemental Table 1. The first clear data point emerging from our analysis was the reduction of circulating lymphocytes compared with a cohort of healthy controls, as already reported (27). Circulating basophils and eosinophils were also significantly lower in patients with COVID-19, whereas neutrophils were higher in patients than in controls. Thus, no differences were observed in the total number of WBCs. By investigating which population of lymphocytes was mainly affected, we found that all subsets, namely...
T, B, and NK cells, were reduced. Among CD3+ T cells, we found a reduction in both CD4+ and CD8+ subsets, but also in the CD56+ fraction, namely the NKT subset. Interestingly, the reduction of the T cell number was more pronounced in the CD8+ cytotoxic cells than in the CD4+ Th subset. Despite the reduction of total absolute numbers of B cells in patients with COVID-19, only transitional B cells exhibited substantially lower levels than reference ranges.

This finding, together with a deep characterization of B cell functions, will require additional investigations in the future. The picture was quite different when T cells, in particular the CD8+ subset, were analyzed. Indeed, we found a marked increase of TEMRA and CD57+CD8+ cells with a parallel decrease of the naive subset, indicating an enrichment of senescent cytotoxic CD8+ T cells. These data are in agreement with previous studies performed on acute...
and chronic viral infections showing that in these conditions, CD8+ T cells acquire an exhausted senescent phenotype (31, 32). Accordingly, when we analyzed the ability of CD4+ and CD8+ T lymphocytes and NK cells to produce cytokines after polyclonal stimulation in vitro, we found in patients with COVID-19 reduced frequencies of IFN-γ–producing cells in both CD4+ and CD8+ T cells, as well as lower frequencies of TNF-α–producing cells among NK cells. Interestingly, patients with COVID-19 showed a significant reduction of CD8+ polyfunctional cell subsets, which have been described as highly protective in virus-infected patients (26). These findings demonstrated that patients with COVID-19 exhibit not only lower numbers of lymphocytes but also a decreased capacity to produce TNF-α and IFN-γ, 2 cytokines that play an important role in the clearance of intracellular pathogens (33).

To further explore the capacity of the immune system to clear the infection, we next moved to the evaluation of the cytolytic potential of each lymphocyte subset, and we found that in patients with COVID-19, intracellular expression of granzyme by circulating NK was significantly lower than in healthy controls. Perforin showed the same trend, even if not statistically significant. Collectively, these data demonstrated that COVID-19 patients have a functionally impaired antiviral response.

In order to try to correlate this impairment with disease activity, we divided our cohort of patients in 2 groups, non-ICU patients and ICU patients, searching for differences in terms of immunological functions and/or serological markers of disease activity. Interestingly, when the cytolytic potential was assessed, we found lower frequencies of granzyme A-expressing NK cells in the ICU group compared with the non-ICU group. In addition, the ICU patients showed lower numbers of circulating CD3+CD4+ and NK lymphocytes and higher levels of serum IL-6. Moreover, serum IL-6 levels inversely correlated with the frequency of granzyme A-expressing NK cells. The observation that serum IL-6 levels correlate with the impairment of cytotoxic activity in COVID-19 patients is in agreement with some reports in the literature demonstrating that, both in murine and in human settings, exposure to high levels of IL-6 inhibits NK cell cytotoxicity and downregulates the expression of perforin and granzyme (34–37).

IL-6 is a pleiotropic, proinflammatory, multifunctional cytokine produced by a variety of cell types, whose serum levels are elevated in various inflammatory and autoimmune disorders such as rheumatic diseases and cytokine release syndrome (38). The possibility of using an anti–IL-6 receptor (IL-6R) mAb in COVID-19 patients is emerging as a potential therapeutic option and is currently under evaluation in Chinese and Italian clinical trials (39, 40).

Starting from this background, we took the opportunity to evaluate 5 patients with COVID-19 in the ICU who underwent off-label treatment with tocilizumab. These patients were evaluated before and after (72 hours) tocilizumab treatment. All patients treated with tocilizumab displayed an increased expression of both perforin and granzyme A in NK cells and a parallel decrease of CRP, which is considered a marker of IL-6-mediated inflammation. Four out of 5 patients also showed a mild increase of the PaO2/FiO2 ratio, even if this observation is not sufficient to sustain the claim that tocilizumab has clinical efficacy. Our data are in agreement with studies showing that exuberant inflammatory responses caused by pathogenic human coronaviruses reduce T cell responses (41). Regarding SARS-CoV infection, this event occurs via a TNF-mediated T cell

---

**Figure 5. Immune cell functional characterization in non-ICU versus ICU hospitalized COVID-19 patients.** (A) Frequency of IL-2–producing cells among CD4+ and CD8+ T cells following in vitro polyclonal stimulation in non-ICU (black dots) and ICU hospitalized patients (gray dots). Frequency of IFN-γ (B) and TNF-α (C) cells among CD4+ and CD8+ T cells and NK cells after in vitro polyclonal stimulation in non-ICU (black dots) and ICU hospitalized patients (gray dots). Frequency of perforin–expressing cells (D) and granzyme A–expressing cells (E) among CD4+ and CD8+ T cells and NK cells in non-ICU (black dots) and ICU hospitalized patients (gray dots). Data obtained from 18 non-ICU and 12 ICU COVID-19 patients. Red lines represent mean values for each population. **P < 0.01; calculated with Student’s t test.
and the impairment of cytotoxic activity suggests the possibility that this cytokine may be responsible for the impairment of cytotoxic lymphocytes, directly or indirectly. This hypothesis is further strengthened by the recovery of perforin and granzyme A expression in NK cells after IL-6R treatment. In this view, the therapeutic blocking of the IL-6 axis should be considered as a mechanism not only to suppress noxious systemic inflammation but also to restore the protective antiviral potential.

In conclusion, the present work suggests that targeting inflammation is a promising tool for the treatment of COVID-19 and provides evidence of the biological mechanism by which tocilizumab can contribute to the clearance of SARS-CoV-2 infection.

Methods

Patients. Thirty patients infected with SARS-CoV-2 were recruited at the Careggi University Hospital (Azienda Ospedaliero-Universitaria
Careggi), Florence, Italy, by the Infective and Tropical Diseases Unit and the Intensive Care Units. SARS-CoV-2 infection was confirmed by routine diagnostic PCR amplification of viral genes from nasopharyngeal swabs. Thirty blood donors were recruited as healthy controls. The median age of healthy controls was 63.5 years, the mean age was 64.2 years, and 50% of the patients were males (Supplemental Table 4). All patients and controls were white. For the longitudinal study, peripheral blood samples were collected before and 72 hours after tocilizumab treatment. Tocilizumab dosage was 8 mg/kg of body weight, followed by 8 mg/kg after 12 hours.

**Immunophenotyping by flow cytometry.** For the analysis of lymphocyte cell subsets by surface marker expression, an aliquot (600 μL) of blood specimens was incubated with ammonium chloride for 5 minutes at room temperature (RT) to lyse red blood cells. After washes in PBS plus BSA 0.5%, the resulting WBCs were stained for 15 minutes with fluorochrome-conjugated monoclonal antibodies (mAbs). A list of all fluorochrome-conjugated mAbs is in Supplemental Table 5. Samples were acquired on a BD LSR II flow cytometer (BD Biosciences). All flow cytometric analyses were performed following published guidelines (46).

**Evaluation of cytokine production by flow cytometry.** PBMCs were obtained after density gradient centrifugation of blood samples. PBMCs were then polyclonally stimulated for 5 hours with PMA (10 ng/mL) and ionomycin (1 μM), the last 3 in the presence of brefeldin A (5 μg/mL). Cells were then fixed in formaldehyde 2% for 15 minutes at RT, washed in PBS plus BSA 0.5%, and then intracellularly stained with fluorochrome-conjugated mAbs in the presence of the permeabilizing agent saponin (0.5%). A list of all fluorochrome-conjugated mAbs used is in Supplemental Table 5. Samples were acquired on a BD LSR II flow cytometer (BD Biosciences).

**Evaluation of cytotoxic molecules by flow cytometry.** PBMCs were directly fixed and intracellularly stained as previously described using fluorochrome-conjugated mAbs (Supplemental Table 5). Samples were acquired on a BD LSR II flow cytometer (BD Biosciences).

**Serum cytokine detection.** Dosages of serum IL-6 were performed using an IL-6 human instant ELISA kit (Invitrogen, Thermo Fisher Scientific) on an automated DSX instrument (DYNEX Technologies).

**Statistics.** An unpaired 2-tailed Student’s t test was used for comparison of clinical and laboratory findings and for flow cytometric analysis of healthy controls versus COVID-19 patients and ICU versus non-ICU COVID-19 patients. Paired 2-tailed Student’s t test was used for comparison of data obtained before and after tocilizumab administration. P values equal to or less than 0.05 were considered significant. Pearson correlation coefficients were used to calculate the correlations.

**Study approval.** The procedures followed in the study were approved by the Careggi University Hospital Ethical Committee (protocol 16859). Written informed consent was obtained from recruited patients.

**Author contributions**

F Liotta, F Annunziato, L Cosmi, and AB designed research studies; A Mazzoni, LS, LM, MC, A Vanni, AA, RC, BP, A Maturici, and A Vultaggio conducted experiments; A Mazzoni, LS, LM, MC, MS, JM, LZ, F Liotta, F Almerigogna, and L Cosmi acquired data; A Mazzoni, LS, LM, MC, F Liotta, F Almerigogna, and L Cosmi analyzed data; MS, JM, MT, LZ, LG, L Ciani, CL, PF, F Lavorini, AP, and AB collected peripheral blood samples and acquired informed consent; F Annunziato, LC, F Liotta, A Mazzoni, LS, and LM wrote the manuscript; SR, F Almerigogna, PP, GMR, and OR provided advice. All authors revised the manuscript and gave final approval for publication.

**Acknowledgments**

This study was supported by funds from the Department of Experimental and Clinical Medicine of University of Florence (ex-60% and the “Excellence Departments 2018–2022 Project”) derived from Ministero dell’Istruzione, dell’Università e della Ricerca (Italy).

Address correspondence to: Francesco Annunziato, Viale Pieraccini 6, 50139, Florence, Italy. Phone: 39.0552758337; Email: francesco.annunziato@unifi.it.


